<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02217007</url>
  </required_header>
  <id_info>
    <org_study_id>SNC-102-211 TS</org_study_id>
    <nct_id>NCT02217007</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome</brief_title>
  <official_title>A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synchroneuron Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synchroneuron Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in&#xD;
      adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102&#xD;
      800 mg on a BID basis - before breakfast and at bedtime - for 4 weeks and the same subjects&#xD;
      will be treated with SNC-102 1600mg in the morning and 800mg in the evening for an additional&#xD;
      4 weeks. Subjects will be assessed for changes in tic severity, safety, and pharmacokinetics.&#xD;
      The study hypothesis is that treatment with SNC-102 will improve the tic severity in adult&#xD;
      subjects with Tourette Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding stopped, company closed&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in total tic severity score on the Yale Global Tic Severity Scale at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determine whether SNC-102 800 mg twice daily (BID) will decrease tic severity in adult patients with Tourette Syndrome (TS), as measured by changes from baseline to 4 weeks in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in total tic severity score on the Yale Global Tic Severity Scale at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determine whether SNC-102 1600 mg in the morning and 800 mg in the evening will decrease tic severity in adult patients with Tourette Syndrome (TS) as measured by change from baseline to Day 57 in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability</measure>
    <time_frame>2, 4, 6, 8, 11 weeks</time_frame>
    <description>Assess the safety and tolerability of SNC-102 in the adult TS population, including assessing the effects, if any, of SNC-102 on symptoms of depression, anxiety, obsessive-compulsive disorder (OCD), and attention deficit-hyperactivity disorder (ADHD);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate clinical effects of SNC-102 on tic severity at 2 weeks and 6 weeks</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS total tic severity score at 2 weeks and 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of SNC-102 in Tourette Syndrome subjects</measure>
    <time_frame>2, 4, 6, 8 weeks</time_frame>
    <description>Assess the pharmacokinetics (PK) of acamprosate administered as SNC-102, including measures of the plasma concentration at 3 hours post-dose (C3h) and the trough plasma concentration (Cmin). The pharmacokinetic analysis will be based on the pre-dose and 3 hour post-dose plasma concentrations of acamprosate on the first day of dosing (Baseline) and on the Day 15, Day 29, Day 43 and Day 57 visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore relationship between study drug plasma levels and the magnitude of clinical response</measure>
    <time_frame>2, 4, 6, 8 weeks</time_frame>
    <description>Explore the relationship between steady-state acamprosate plasma levels and the magnitude of clinical response to the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate clinical effects of SNC-102 on Global Clinical Impression</measure>
    <time_frame>2, 4, 6, 8, 11 weeks</time_frame>
    <description>Evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Clinical Global Impression (CGI) at all post-baseline visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate clinical effects of SNC-102 on tic severity sub scales</measure>
    <time_frame>2, 4, 6, 8, 11 weeks</time_frame>
    <description>Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS sub scales at all visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>SNC-102 sustained release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNC-102 sustained release tablet</intervention_name>
    <description>SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.</description>
    <arm_group_label>SNC-102 sustained release tablet</arm_group_label>
    <other_name>SNC-102</other_name>
    <other_name>acamprosate calcium sustained release tablet</other_name>
    <other_name>acamprosate calcium</other_name>
    <other_name>acamprosate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis by a Board-certified neurologist or psychiatrist of Tourette Syndrome&#xD;
             according to Diagnostic and Statistical Manual (DSM)-V criteria for Tourette's&#xD;
             Disorder, viz.&#xD;
&#xD;
          -  Both multiple motor and one or more vocal tics have been present at some time during&#xD;
             the illness, although not necessarily concurrently.&#xD;
&#xD;
          -  The tics may wax and wane in frequency but have persisted for more than 1 year since&#xD;
             first tic onset.&#xD;
&#xD;
          -  Onset is before age 18 years.&#xD;
&#xD;
          -  The disturbance is not attributable to the physiological effects of a substance (e.g.,&#xD;
             cocaine) or another medical condition (e.g., Huntington's disease, postviral&#xD;
             encephalitis).&#xD;
&#xD;
          -  Moderate to severe tics as indicated by a Clinical Global Impression (CGI) score of 4&#xD;
             or higher on both the Screening Visit and the Baseline Visit while on their usual drug&#xD;
             therapy for Tourette Syndrome.&#xD;
&#xD;
          -  If using a permitted medication (SSRI, Serotonin-norepinephrine reuptake inhibitors&#xD;
             (SNRI), alpha-2 agonist, benzodiazepine, dopamine antagonist, or stimulant) the dose&#xD;
             has been stable for at least 4 weeks prior to the Screening Visit and is expected to&#xD;
             remain stable through the conclusion of the study.&#xD;
&#xD;
          -  Ability to swallow investigational tablets whole and without chewing, as demonstrated&#xD;
             by swallowing a placebo tablet at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of epilepsy.&#xD;
&#xD;
          -  Treatment with an antiepileptic drug with the exception of a stable dose of&#xD;
             clonazepam. Topiramate and lamotrigine are specifically excluded.&#xD;
&#xD;
          -  Unstable psychiatric status, as indicated by any change in psychotropic medication&#xD;
             (unless approved by the Sponsor), or by psychiatric hospitalization, within 30 days&#xD;
             prior to the Screening Visit.&#xD;
&#xD;
          -  Active drug or alcohol dependence or abuse.&#xD;
&#xD;
          -  Current use of cocaine, amphetamine, phencyclidine, or ketamine, documented either by&#xD;
             history or by urinary drug screening at Screening and Baseline Visits. Drugs used to&#xD;
             treat attention deficit-hyperactivity disorder or obsessive-compulsive symptoms are&#xD;
             allowed if stable for at least 4 weeks prior to the Screening Visit and are expected&#xD;
             to remain stable through the course of the trial. Any other drugs identified on drug&#xD;
             screening will warrant exclusion only if the Principal Investigator, in consultation&#xD;
             with the Sponsor, judges that their presence could interfere with the objectives of&#xD;
             the trial.&#xD;
&#xD;
          -  Risk of significant medication non-adherence, based on the judgment of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome.&#xD;
&#xD;
          -  Significant risk, in the judgment of the Principal Investigator, of suicidal or&#xD;
             violent behavior.&#xD;
&#xD;
          -  Female subjects with a history of pre-menstrual exacerbation of tics.&#xD;
&#xD;
          -  Initiation of oral contraceptive medication, insertion of progestin contraceptive&#xD;
             implant, or change in dose, within 30 days prior to the Screening Visit, or&#xD;
             anticipated while participating in the trial.&#xD;
&#xD;
          -  History of short-bowel or other malabsorption syndrome, gastrointestinal hypermotility&#xD;
             of any cause, or any gastrointestinal disease or surgery that, in the judgment of the&#xD;
             Principal Investigator, could interfere with absorption of orally-administered&#xD;
             medication, reduce intestinal transit time or pre-dispose to gastric outlet&#xD;
             obstruction.&#xD;
&#xD;
          -  Allergy or intolerance to acamprosate.&#xD;
&#xD;
          -  Prior treatment with acamprosate for any indication.&#xD;
&#xD;
          -  Known human immunodeficiency virus or acquired immunodeficiency syndrome-related&#xD;
             illness.&#xD;
&#xD;
          -  Use of any investigational agents within 4 weeks of Baseline.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry S Fogel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Synchroneuron Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital, Dept. of Psychiatry</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette</keyword>
  <keyword>Tourette's</keyword>
  <keyword>tic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02217007
org study id: SNC-102-211 TS
nct id: NCT02217007
lead sponsor: 
has dmc: No
This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in
      adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102
      800 mg on a BID basis - before breakfast and at bedtime - for 4 weeks and the same subjects
      will be treated with SNC-102 1600mg in the morning and 800mg in the evening for an additional
      4 weeks. Subjects will be assessed for changes in tic severity, safety, and pharmacokinetics.
      The study hypothesis is that treatment with SNC-102 will improve the tic severity in adult
      subjects with Tourette Syndrome.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Improvement in total tic severity score on the Yale Global Tic Severity Scale at 4 weeks
time frame: 4 weeks
description: Determine whether SNC-102 800 mg twice daily (BID) will decrease tic severity in adult patients with Tourette Syndrome (TS), as measured by changes from baseline to 4 weeks in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).
measure: Improvement in total tic severity score on the Yale Global Tic Severity Scale at 8 weeks
time frame: 8 weeks
description: Determine whether SNC-102 1600 mg in the morning and 800 mg in the evening will decrease tic severity in adult patients with Tourette Syndrome (TS) as measured by change from baseline to Day 57 in the total tic severity score on the Yale Global Tic Severity Scale (Y-GTSS).
measure: Assess safety and tolerability
time frame: 2, 4, 6, 8, 11 weeks
description: Assess the safety and tolerability of SNC-102 in the adult TS population, including assessing the effects, if any, of SNC-102 on symptoms of depression, anxiety, obsessive-compulsive disorder (OCD), and attention deficit-hyperactivity disorder (ADHD);
measure: Evaluate clinical effects of SNC-102 on tic severity at 2 weeks and 6 weeks
time frame: 2, 6 weeks
description: Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS total tic severity score at 2 weeks and 6 weeks
measure: Pharmacokinetic profile of SNC-102 in Tourette Syndrome subjects
time frame: 2, 4, 6, 8 weeks
description: Assess the pharmacokinetics (PK) of acamprosate administered as SNC-102, including measures of the plasma concentration at 3 hours post-dose (C3h) and the trough plasma concentration (Cmin). The pharmacokinetic analysis will be based on the pre-dose and 3 hour post-dose plasma concentrations of acamprosate on the first day of dosing (Baseline) and on the Day 15, Day 29, Day 43 and Day 57 visits.
measure: Explore relationship between study drug plasma levels and the magnitude of clinical response
time frame: 2, 4, 6, 8 weeks
description: Explore the relationship between steady-state acamprosate plasma levels and the magnitude of clinical response to the drug.
measure: Evaluate clinical effects of SNC-102 on Global Clinical Impression
time frame: 2, 4, 6, 8, 11 weeks
description: Evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Clinical Global Impression (CGI) at all post-baseline visits
measure: Evaluate clinical effects of SNC-102 on tic severity sub scales
time frame: 2, 4, 6, 8, 11 weeks
description: Further evaluate the clinical effects of SNC-102 in this population as measured by changes from baseline in Y-GTSS sub scales at all visits
arm group label: SNC-102 sustained release tablet
arm group type: Experimental
description: SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
intervention type: Drug
intervention name: SNC-102 sustained release tablet
description: SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
arm group label: SNC-102 sustained release tablet
other name: SNC-102
other name: acamprosate calcium sustained release tablet
other name: acamprosate calcium
other name: acamprosate
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Barry S Fogel, MD
role: Study Director
affiliation: Synchroneuron Inc.
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Tourette Syndrome
mesh term: Syndrome
mesh term: Calcium, Dietary
mesh term: Acamprosate
mesh term: Calcium